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Objectives: Valve allografts produce an immune response, which can influence their
performance. The exact role of the interaction between recipient T cells and the dif-
ferent cellular components of the donor valve in stimulating an immune response is
not known. Therefore the T-cell response to valve endothelial and interstitial cells
was investigated in vitro.
Methods: Valve endothelial and interstitial cells were characterized for cell-surface
molecules before and after interferon γ treatment by means of a panel of specific
monoclonal antibodies and flow cytometry. The proliferative response of highly
purified T lymphocytes was used to assess the immunogenicity of cultured valve
endothelial and interstitial cells. This was further investigated by using a 2-step tol-
erance-induction protocol.
Results: Valve endothelial and interstitial cells express similar levels of human leuko-
cyte antigens and adhesion and costimulatory molecules, which are either induced or
upregulated after interferon γ treatment. T-cell responses to endothelial cells were
detected after interferon γ treatment, but responses to interferon γ–treated interstitial
cells were not detected. This lack of response resulted in the induction of T-cell aner-
gy, which was reversed by the presence of the costimulatory molecule B7-1.
Conclusions: Although valve endothelial and interstitial cells express a similar
range of cell-surface molecules, it is only the endothelial cells that are immuno-
genic. In addition, we have shown that these 2 cell types interact in a donor-
specific manner to orchestrate the immune response and therefore may have clini-
cal relevance in the allogeneic response of the heart valve recipients.
Transplantation of human cardiac valve homografts is successful withgood long-term results in the absence of immunosuppressive thera-py.1,2 Blood group or HLA antigens between donor and recipient arenot matched because it is thought that antigenicity is minimal as aresult of the lack of blood vessels in the cardiac valves. Nevertheless,it is highly possible that homografts can be damaged as shown by
donor-specific immune responses, which lead to immunologic damage by both
humoral and cellular factors.3-6 This has been shown to be particularly evident in
children who receive valvular allografts.7-9
Although evidence that human valve allografts are immunogenic is limited, the
underlying cellular mechanisms involved are still unclear. Endothelial cells, normally
the barrier between blood and tissue, have long been implicated in provoking immune
responses between the allograft and the recipient’s immune cells, leading to rejec-
tion.10-12 This has been demonstrated in vitro by using endothelial cells cultured from
valve leaflets that are capable of eliciting T-cell responses.13,14 This would then sug-
gest that valve allografts that are lined with endothelium would be rejected. Low
doses of antibiotics used to preserve the valves may lower the immunogenicity of the
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valves.15 However, the interplay between the endothelium
and other cells, such as the interstitial cells, that make up the
valves may provide an insight into the cellular mechanisms
involved in rejection. In this study we have used highly puri-
fied human T cells to investigate the relative immunogenicity
of both the human valve endothelial and interstitial cells mis-
matched at the DR locus.
Materials and Methods
Isolation and Culture of Cells
Interstitial and endothelial cells were isolated from either valve leaflets
or donor aorta by means of differential enzymatic digestion, as previ-
ously described,15,16 and cultured in tissue culture–grade flasks. Skin
and pericardial fibroblasts were isolated as previously described16
from either the human forearm from a group of normal control sub-
jects, from a genetic screening program, or from a trimmed piece of
pericardium from transplant recipients, respectively.
The purity of the endothelial and interstitial cells was determined
by means of flow cytometry after staining with monoclonal antibod-
ies (mAbs) against either endothelial cells (EN4, Monosan; TCS
Biologicals, Buckingham, United Kingdom) or fibroblasts (anti-
fibroblast antibody; Dianova, Hamburg, Germany). Differential col-
lagenase treatment usually yielded a purity of 50% to 95% endothe-
lial cells and 10% to 90% fibroblasts. Ulex-coated Dynabeads
(Dynal, Bromborough, United Kingdom), which specifically bind
endothelial cells, were used as specified by manufacturer’s instruc-
tions to improve purity to greater than 95% endothelial cells. This
method yielded greater than 95% endothelial cells. Endothelial cells
were used between passages 6 and 9 and were used for experiments
if their purity was greater than 95%. Interstitial cells were used
between passages 6 and 9, and their purity was confirmed before each
experiment by means of the anti-fibroblast antibody. Interstitial cells
were only used if purity was greater than 95%. The phenotype of the
interstitial cells has been shown not to change up to passage 10 with
regard to fibroblast surface antigen and smooth muscle α-actin.16 The
phenotype of valve endothelial cells also did not change with regard
to EN4 (personal communication, Dr Patricia Taylor, National Heart
and Lung Institute, Imperial College, United Kingdom). The pheno-
types of both valve endothelial and interstitial cells were found to be
relatively consistent.
For experiments, both endothelial and interstitial cells were
used either untreated or treated with recombinant human interfer-
on γ (IFN-γ; 500 U/mL for 4 days). Endothelial cells were cultured
from aortic valves, mitral valves, tricuspid valves, and veins of
umbilical cords (isolation is described elsewhere17), whereas inter-
stitial cells were cultured from aortic valves, mitral valves, tricus-
pid valves, pericardium, and skin. Tissue was obtained from heart
transplant recipients with no previous history of heart valve disease
after ethical approval. Pericardial tissue was dissected at the time
of transplantation from recipient hearts.
Cell Lines
DAP.B718 is a major histocompatibility complex (MHC) class
II–negative mouse L-cell fibroblast transfectant cell line express-
ing surface human B7-1 (CD80) molecules (a gift from Professor
R. I. Lechler, Imperial College, London, United Kingdom).
Monoclonal Antibodies and Flow Microfluorimetric
Analysis
Anti-HLA class I mAb (W6/32), anti-HLA class II mAb (L243,
DRα), and anti-intercellular adhesion molecule 1 (CD54 or
ICAM-1) were used at saturating concentrations (ATCC,
Rockville, Md). Anti-lymphocyte function-associated antigen 3
(CD58 or LFA-3; Serotec, Oxford, United Kingdom) and anti-
CD40 (Serotec) were used at 10 µg/mL. Mouse chimeric protein,
cytotoxic T-cell activation antigen 4 human immunoglobulin γ
heavy chain (a kind gift of Peter Lane, Basel Institute of
Immunology, Switzerland), was used to stain the family of costim-
ulatory molecules termed B7 at saturating concentration.
Surface antigen expression on interstitial and endothelial cells
was measured with indirect immunofluorescence and flow micro-
fluorimetric analysis, as previously described.19 Secondary anti-
bodies used were either fluorescein isothiocyanate–conjugated
rabbit anti-mouse immunoglobulin (Dako Ltd) or fluorescein
isothiocyanate–conjugated sheep anti-human immunoglobulin G
(γ chain; Binding Site, Birmingham, United Kingdom). Cells were
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Figure 1. Purified human CD4+ T cells but not CD8+ T cells prolif-
erate to valve endothelial cells. Data are expressed as mean
counts per minute ± SD of triplicate wells for T-cell proliferation.
Figure 2. Valve interstitial cells do not elicit CD4+ T-cell prolifera-
tion. Data are expressed as mean counts per minute ± SD of trip-
licate wells for T-cell proliferation.
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analyzed on an EPICS XL-MCL Flow Cytometer (Beckman
Coulter, High Wycombe, United Kingdom).
Purification of Human CD4+ and CD8+ T Cells
This method has been described in detail elsewhere.20 CD4+ and
CD8+ T cells were purified from peripheral blood mononuclear
cells collected from normal individuals by means of a 2-step neg-
ative selection method. First, adherent cells were depleted by incu-
bation on tissue-culture grade petri dishes for 1 hour at 37°C.
Nonadherent cells were then eluted and washed. Second, magnet-
ic immunoselection with a MidiMACS column (LS+) and a CD4+
or CD8+ T-cell isolation kit was used, as specified by manufactur-
er’s instructions (Miltenyi Biotec, Surrey, United Kingdom). Flow
microfluorimetric analysis indicated that more than 99% of the
Figure 3. Phenotypic characterization of endothelial and interstitial cells cultured from valve and nonvalve tissue.
Expression of cell-surface antigens before and after IFN-γ treatment was carried out with appropriate mAbs
against HLA class I, HLA class II, CD40, lymphocyte function-associated antigen 3 (LFA-3), and intercellular adhe-
sion molecule 1 (ICAM-1), as described in the “Materials and Methods” section. The negative controls were fluo-
rescein isothiocyanate–conjugated anti-mouse secondary antibodies only. Data are expressed as percentages of
positive staining.
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resulting cells stained positively for CD4 or CD8 and CD3, and
less than 2% were stained with the other non–T-cell antibodies.
The purity of the CD4+ or CD8+ T cells was further established by
nonresponsiveness to phytohemagglutinin stimulation.
T-Cell Proliferation Assays
Purified T cells (105) were cocultured with stimulator cells (2.5 ×
104 untreated or IFN-γ–treated endothelial or interstitial cells) for
6 days in a humidified carbon dioxide incubator at 37°C. In some
experiments DAP.B7 (2.5 × 104) was also added with the intersti-
tial cells at the time of seeding. Proliferation of responder T cells
was determined by the addition of tritiated thymidine (1 µCi/well,
Amersham Corp, Arlington Heights, Ill) for the last 18 hours of
culture. The samples were harvested onto glass fiber filters, and tri-
tiated thymidine incorporation was determined with a Wallac 1450
Microbeta Trilux β-counter (Wallac, EG&G, Milton Keynes,
United Kingdom). Results are expressed as mean counts per
minute for triplicate samples ± SD. All experiments were per-
formed on at least 5 different occasions, and representative results
are shown in each case.
Two-Step Anergy Induction
Purified CD4+ T cells (3 × 106 cells per well in a 6-well plate) were
cocultured with either recombinant human IFN-γ–treated (500
U/mL for 4 days) or untreated interstitial cells (7.5 × 105 cells per
well in a 6-well plate) for 24 hours. In some experiments mAbs
were also added. Controls also included T cells alone. T cells were
then removed from the interstitial cells and challenged (105) with
either 2.5 × 104 IFN-γ–treated valve endothelial cells from the
same donor or with complete DR-mismatched third-party valve
endothelial cells. After 6 days, T-cell proliferation was determined,
as described previously. All experiments were performed on at
least 5 different occasions, and representative results are shown in
each case.
Results
It has been previously shown that both macrovascular and
microvascular endothelial cells are capable of activating and
inducing T-cell proliferation in human and mouse in vitro
models.21,22 A typical example from 6 independent experi-
ments showed that only purified CD4+ and not CD8+ T cells
responded to IFN-γ–treated aortic valve endothelial cells
mismatched at both DR loci in a dose-dependent manner
(Figure 1). Similar results were obtained with endothelial
cells isolated from other valve tissue, such as tricuspid and
mitral valves.
However, when interstitial cells cultured from the same
valves as the endothelial cells were cocultured with purified
CD4+ T cells, there was either little or no response. This was
evident with cells from aortic, tricuspid, and mitral valves,
as well as from donor aorta (Figure 2). Therefore, endothe-
lial and interstitial cells from various valve and nonvalve tis-
sues were characterized for possible differences in their
cell-surface expression of various costimulatory, adhesion,
and MHC molecules before and after treatment with IFN-γ
to investigate why valve interstitial cells are such poor T-cell
stimulators. We used skin fibroblasts and human umbilical
vein endothelial cells as controls for comparing valve inter-
stitial and endothelial cells, respectively.
As shown in Figure 3, constitutive expression of MHC
class I was upregulated after IFN-γ treatment (the mean
fluorescence intensity, an arbitrary unit for levels of cell-
surface molecules per cell, was generally increased by a fac-
tor of 8 to 10 times; data not shown). MHC class II expres-
sion was induced or increased from 0% to 5% to a maxi-
mum of 100% positive in all the cells tested, indicating that
both endothelial cells and interstitial cells from the valve are
capable of cognate interactions with the T-cell receptor. The
costimulatory adhesion molecules CD40, lymphocyte func-
tion-associated antigen 3, and intercellular adhesion mole-
cule 1 were all upregulated after IFN-γ treatment both in the
valve endothelial and interstitial cells, albeit not all to the
same extent. This may be due to interisolate variations.
Nevertheless, it is clear that both valve endothelial and inter-
stitial cells do not differ greatly in their expression of co-
stimulatory and adhesion molecules. We did, however, fail
to find expression of the family of costimulatory molecules
called B7 (CD80/CD86) in all the cells tested before or after
IFN-γ treatment (data not shown).
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Figure 4. Valve interstitial cells induce a state of T-cell nonre-
sponsiveness. A, CD4+ T cells respond to both IFN-γ–treated mitral
valve endothelial cells 58 (MV58 EC) and to third-party tricuspid
valve endothelial cells (TV71 EC) for 6 days. B, The 2-step toler-
ance-induction protocol described in the “Materials and
Methods” section was used. Data are expressed as mean counts
per minute ± SD of triplicate wells.
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Experiments with a 2-step tolerance induction method
were used to further investigate the lack of T-cell response to
valve interstitial cells. By using valve interstitial and endothe-
lial cells from the same valve tissue (MV58), we confirmed
that only IFN-γ–treated endothelial cells and not interstitial
cells elicited a primary T-cell alloresponse (Figure 4, A).
Similarly, a strong primary T-cell alloresponse was elicited to
the third-party valve endothelial cell control (TV71). The dif-
ferences in the magnitude of the primary responses between
MV58 and TV71 endothelial cells can be attributed to inter-
isolate variations, particularly because the endothelial cell
populations were mismatched at both DR loci with the
responding T cells. However, if the T cells were cocultured
with the interstitial cells first and then rechallenged with
endothelial cells from the same valve tissue, the T cells com-
pletely failed to respond (Figure 4, B). A state of MHC-
specific T-cell nonresponsiveness or anergy was induced,
whereas T-cell responses to third-party endothelial cells were
still intact. Indeed, if T cells were cocultured with either
untreated MV58 interstitial cells (no MHC class II expres-
sion) or just on plastic before rechallenge, secondary T-cell
responses to both MV58 and TV71 valve endothelial cells
were equivalent to those seen in the primary T-cell responses
(Figure 4, A). To further confirm that T-cell anergy was MHC
class II restricted, the addition of anti-MHC class II mAb
L243 during the primary coculture step completely abolished
the induction of T-cell nonresponsiveness to MV58 endothe-
lial cells. However, it was interesting to find that the addition
of anti-CD40 mAb did not reverse T-cell energy.
Full T-cell activation requires 2 signaling events. The
first is an antigen-specific signal delivered by the MHC-
antigen complex interacting with the T-cell receptor, and the
crucial second signal has been defined as costimulation.23,24
To confirm that the lack of T-cell responsiveness to valve
interstitial cells is due to either partial or absent second sig-
nals, transcostimulation provided by human B7-1 presented
on a bystander cell (DAP.B7) rescued the absent T-cell
responses to IFN-γ–treated valve interstitial cells (TV84 IC)
with more than comparable T-cell stimulation, as seen
against the IFN-γ–treated valve endothelial cells (TV84 EC)
from the same valve tissue (Figure 5). However, there was
no response to DAP.B7 alone, indicating that DAP.B7 itself
is not capable of stimulating CD4+ T cells alone.
Discussion
Previous clinical and experimental studies have indicated
that cardiac valve tissue is immunogenic, as shown by the
presence of anti-donor HLA antibodies in patients after aor-
tic valve replacement3,4,9 and by T-cell alloresponses to
endothelial cells isolated from fresh and cryopreserved
valves in vitro.14,25,26 In the present study the latter findings
have been confirmed, where endothelial cells from various
valve tissues were found to stimulate CD4+ T cells.
However, interstitial cells cultured from the same valve
leaflets were found to be relatively nonimmunogenic.
Phenotypically, the valve interstitial cells were very simi-
lar to the valve endothelial cells when the expression of var-
ious adhesion, costimulatory, and HLA molecules was com-
pared before and after treatment with IFN-γ. Yet only the
valve endothelial cells were capable of stimulating T cells in
a B7-independent manner. Immunohistochemical staining of
valve leaflets has shown that the layer of endothelial cells
covering the surface is constitutively HLA class II positive,
and like most other human endothelial cells isolated from tis-
sue, subsequent culture in vitro sees the loss of constitutive
HLA class II expression until stimulated with IFN-γ. Unlike
the endothelial cells, valve interstitial cells are HLA class II
negative within the native valve leaflet and remain HLA
class II negative in in vitro culture until stimulated with IFN-
γ (personal communication, Dr Patricia Taylor, National
Heart and Lung Institute, Imperial College, United
Kingdom). Human endothelial cells have been described to
be devoid of the presence of both the transcript and protein
for the family of B7 molecules.27,28 Valve endothelial cells,
as well as interstitial cells, also show absence of B7 molecule
expression. However, whether the cells display B7 in the
native valve leaflet still remains to be elucidated.
However, when primary CD4+ T cells are cocultured with
HLA class II–expressing valve interstitial cells, the T cells
become refractory to further stimulation by valve endothelial
cells expressing the same HLA antigens. The indication that
the T cells were still viable and that the nonresponsiveness
was DR restricted was shown by intact responses to both
exogenous IL-2 (data not shown) and third-party DR-
mismatched endothelial cells, respectively. This suggested
that signal 1 (cognate interaction between the T-cell receptor
and the MHC molecule) in T-cell activation was occurring in
Figure 5. T-cell responses to valve interstitial cells are rescued by
B7-1 transcostimulation. CD4+ T cells (105) were cocultured with
2.5 × 104 untreated or IFN-γ–treated TV84 endothelial cells (EC) or
interstitial cells (IC). The transfectant, DAP.B7, which expresses
human B7-1, was also added to either T-cell responses to IFN-
γ–treated TV84 interstitial cells or to T cells alone. Data are
expressed as mean counts per minute ± SD of triplicate wells.
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the absence of signal 2 (costimulation), leading to T-cell non-
responsiveness. It was therefore reassuring to find that the
addition of the costimulatory molecule B7-1 presented on a
bystander cell (DAP.B7) restored full T-cell activation
against the valve interstitial cells. The finding that valve
interstitial cells (or valve fibroblasts) expressing similar lev-
els of adhesion and HLA class II molecules to endothelial
cells lack the ability to initiate allostimulation is not unique.
Other reports have shown that parenchymal cells, such as
human dermal fibroblasts and epithelial cells, are also unable
to stimulate T cells in a similar fashion.29,30 It appears that
these nonprofessional antigen-presenting cells are deficient
in as-yet undefined costimulatory factors, which appear to be
present on endothelial cells. As a consequence of this co-
stimulatory deficiency, we have shown that valve interstitial
cells can induce T-cell anergy. Whether these effects take
place in vivo is difficult to ascertain, but the cellular state of
the valve before implantation may be of crucial importance.
For instance, it may be beneficial to remove the endothelial
cell layer from the valve either manually or by means of
high-dose antibiotic treatment, thus exposing the interstitial
cells for cytokine treatment to upregulate HLA class II mol-
ecules. This in turn may allow them to be accessed and sam-
pled by the recipient’s T cells, which will therefore become
anergic. This may already be a contributory factor within
patients with long-term valve performance. On the other
hand, because endothelial cells normally provide an
antithrombogenic surface, removing the endothelial layer
may lead to a prothrombogenic state. An alternative solution
may be to tissue engineer cardiac valves containing intersti-
tial cells that have been altered to constitutively express HLA
class II molecules in the absence of cytokine treatment. This
approach would circumvent the upregulation of other proin-
flammatory molecules and soluble factors, which might
cause dysfunction and deterioration of the implanted valve.
In conclusion, the present study shows that valve
endothelial cells are relatively immunogenic in vitro, and
therefore their immunogenicity may be extended to donor-
directed immune mechanisms in vivo. To verify and dissect
the actual contribution of an ongoing immunologic response
against the donor valves, prospective studies examining the
frequency of donor-specific T-cell responses in patients
implanted with either cryopreserved or high-dose antibiot-
ic–treated valves may shed some light on how to dampen
the alloresponse. Our results suggest that manipulation of
cell-surface molecules on both the endothelial cells and the
interstitial cells may offer an alternative strategy to divert
the immune response away from the valve allografts.
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